{
    "clinical_study": {
        "@rank": "164914", 
        "acronym": "ESTEEM", 
        "arm_group": {
            "arm_group_label": "dimethyl fumarate (DMF)", 
            "description": "Patients with multiple sclerosis receiving dimethyl fumarate (DMF) under routine clinical care"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of the study is to determine the incidence, type, and pattern of\n      serious adverse events (SAEs), including but not limited to infections (including\n      opportunistic infections), hepatic events, malignancies, and renal events, and of adverse\n      events (AEs) leading to treatment discontinuation in patients with MS treated with DMF.\n      Secondary objectives of this study in this population are as follows:  To determine dimethyl\n      fumarate (DMF) prescription and utilization patterns in routine clinical practice in\n      patients with multiple sclerosis (MS);  To assess the effectiveness of dimethyl fumarate\n      (DMF) on multiple sclerosis (MS) disease activity and disability progression in routine\n      clinical practice as determined by the Expanded Disability Status Scale (EDSS) score and\n      multiple sclerosis (MS) relapse information; and To assess the effect of dimethyl fumarate\n      (DMF) on health-related quality of life, healthcare resource consumption, and work\n      productivity."
        }, 
        "brief_title": "Dimethyl Fumarate (DMF) Observational Study", 
        "completion_date": {
            "#text": "November 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n        -  Patients with multiple sclerosis (MS) who are newly initiating treatment with dimethyl\n        fumarate (DMF) under routine clinical care are eligible to participate in the study.\n\n        Key Exclusion Criteria:\n\n          -  Patients with previous exposure to dimethyl fumarate (DMF), Fumaderm\u00ae, or compounded\n             fumarates.\n\n          -  Patients participating in other clinical studies.\n\n        NOTE:  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients undergoing routine clinical care for Multiple Sclerosis."
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047097", 
            "org_study_id": "109MS401"
        }, 
        "intervention_browse": {
            "mesh_term": "Dimethyl fumarate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gilbert", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fullerton", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Danbury", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Charlotte", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elkhart", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lenexa", 
                        "country": "United States", 
                        "state": "Kansas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edina", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Golden Valley", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarentum", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kogarah", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera\u2122 (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec Investigator"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The number of participants that experience Adverse Events (AEs) that lead to discontinuation of dimethyl fumarate (DMF)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "The number of participants that experience Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047097"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of Dimethyl fumarate (DMF) use", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Dimethyl fumarate (DMF) dosing frequency", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Primary reasons for discontinuation of Dimethyl fumarate (DMF) use", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Frequency of relapses over time", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Disease progression as measured by Expanded Disability Status Scale (EDSS) over time", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Multiple Sclerosis Impact Scale-29 Items (MSIS-29) physical multiple sclerosis (MS) impact score", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Multiple Sclerosis Impact Scale-29 Items (MSIS-29) psychological multiple sclerosis (MS) impact score", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "EuroQol-5 Dimensions (5 Level) (EQ-5D-5L) index score", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "EuroQol Visual Analogue Scale (EQ VAS) (0-100 scale)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Modified Fatigue Impact Scale-5 (MFIS-5) total score", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Work Productivity and Activity Impairment questionnaire: Multiple Sclerosis, Version 2.0 (WPAI-MS) impairment percentages", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Health Care Consumption", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "January 2014"
    }
}